The Light of Hope in Antidepressant Strategies

Article information

Chronobiol Med. 2020;2(2):57-60

Publication date (electronic) : 2020 May 28

doi : https://doi.org/10.33069/cim.2020.0008

Pierre A. Geoffroy^,1,2,3

¹Université de Paris, NeuroDiderot, Inserm, Paris, France

²Department of Psychiatry and Addictive Medicine, Assistance Publique-Hôpitaux de Paris (AP-HP), University Hospital Bichat-Claude Bernard, Paris, France

³Centre des troubles du sommeil-CIRCSom and Institut des Neurosciences Cellulaires et Intégratives, CNRS-UPR 3212, Strasbourg, France

Corresponding author: Pierre A. Geoffroy, MD, PhD, Department of Psychiatry and Addictive Medicine, University Hospital Bichat-Claude Bernard, 46 rue Henri Huchard, 75018, Paris, France. Tel: 33-1-40-25-82-62, E-mail: pierre.a.geoffroy@gmail.com

Received 2020 April 19; Revised 2020 May 11; Accepted 2020 May 11.

Abstract

INTRODUCTION

Light therapy (LT) benefited from major new insights and evidence that have been accumulated over last decades. It is time to consider LT as a first-line treatment in depression and this brief review offers a snapshot of where the actual scientific knowledge stands.

BRIEF LIGHT THERAPY HISTORY OF ITS CLINICAL MOOD EFFECTS

LT is both an old and a new treatment. Old, because LT is used since the Antiquity with sun therapies that were applied in ancient Chinese, Hindu and Egyptian medicine over 15 centuries BC [1]. New, because psychiatry benefited from a recent growing interest in LT since the publication of a case-series of patients successfully treated for seasonal affective disorder (SAD) by Rosenthal et al. [2] in 1984. Since this first documentation of LT in SAD, numerous studies have been published in seasonal depressions and several meta-analyses of randomized trials have confirmed that LT is more efficient than placebo in subjects with both unipolar depression [3] and bipolar depression [4] with seasonal patterns. Interestingly, LT appeared also efficient in non-seasonal unipolar depression [3,5]. LT has been assessed not only as a monotherapy, but is also commonly used as an augmentation strategy to antidepressant drugs (AD) in non-seasonal depression, for both unipolar and bipolar disorders [6,7]. Indeed, in up to 50% to 60% of patients who did not respond to AD monotherapy [8], LT used as an add-on/augmentation strategy increased the response [6]. In addition, a recently published meta-analysis [9] confirmed the need to change practices and recommend a first-line combination treatment in order to maximize patients’ response rates, rather than using LT as a second- or third-line augmentation strategy. This meta-analysis evidence that LT and antidepressants have no superiority among each other, when introduced as a first-line treatment in major depressive episodes (MDE) with and without seasonal pattern, and with a clear superiority of the combination of the two compared with antidepressants alone [9]. This is supporting LT use as an additional excellent first-line antidepressant strategy [9]. Moreover, LT is thus not only the cornerstone treatment of SAD [2], but also should be used as a first-line monotherapy or combination therapy in non-seasonal MDE. In this indication, LT appears also well tolerated in the treatment of adults with moderate to severe non-seasonal unipolar depression, with effect sizes equivalent to those observed in trials using selective serotonin reuptake inhibitors [3,5], as in bipolar disorder [10].

OTHER EFFECTS OF LIGHT IN MOOD DISORDERS

LT has the advantage of being also effective in improving both sleep and circadian rhythms, which may be altered in depression, contrary to AD that target mainly mood [11]. Interestingly first evidence of possible LT efficacy comes from basic neurosciences reporting in 1979 that phase shifts of circadian rhythms could have an antidepressant effect [12] and in 1980 that light suppresses melatonin secretion and so impacts circadian rhythms in humans, like for all other mammals [13]. Thus antidepressant effect of LT may be link to both a phase advance and/or alignment of circadian rhythms, first confirmed by Kripke et al. [14,15] and Lewy et al. [16], but also to more direct effects [17]. Indeed, LT effects are associated with mechanisms that are independent of the circadian clock and act directly on monoaminergic pathways, as suggested with observed efficacy even at midday [17,18]. These direct and indirect effects may explain why light exerts a strong direct and rapid effect on mood [18,19]. LT also enhances alertness with such direct and rapid effect [20] and increases the sleep homeostasis, which regulates the sleep intensity [21]. LT has also demonstrated to improve sleepiness and sustained attention [22]. This multiple possible interesting effects, depending on the clinical manifestations, are dependent on the light dose (determined by light irradiance level, duration of exposure, distance and angle from the light source), light color spectrum, and on the time of day of light exposure [23-25]. Further research are warranted to determine the most efficient lighting parameters to use [26]. Figure 1 summarizes the parameters and effects of LT in mood disorders. Table 1 summarizes the standard protocols for LT in MDE [27].

Figure 1.

Parameters and effects of light therapy in mood disorders.

Table 1.

Standard protocols for light therapy in major depressive episode

PERSPECTIVES

It remains critical to evaluate whether LT can be used as a maintenance treatment, as well as identifying predictive biomarkers of response and tolerability. In addition, light effects and tolerance may depend on depression subtypes, warranting specific further studies. Indeed, depression encompasses very heterogeneous entities such as SAD, unipolar or bipolar subtypes, psychotic, melancholic, etc., which may benefit from different efficient lighting parameters, as in bipolar disorders where patients should be pretreated with an anti-manic mood stabilizer and light be titrated with a daily exposure time starting with 15 minutes (instead of 30 min in unipolar depression) and increased slowly to avoid manic switch [27]. Nevertheless this agenda is possible and very expected only because from a clinical level LT appears as a clear efficient antidepressant strategy that deserve his place in the first-line therapeutic armamentarium of MDE. In line with this, the International Society for Bipolar Disorders (ISBD) task force recently published practice recommendations for LT as a first-line treatment in bipolar depression [28].

Article information Continued